ReviewDigestive diseases (Basel, Switzerland)2005
Treatment of alcoholic liver disease.
Review in Digestive diseases (Basel, Switzerland), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 79 citations in OpenAlex.
- Systemic Consequences of Chronic Ethanol Intake: From Microbiome Shifts to Metabolic Impairment.Comprehensive physiology · 2026Article
- Extraction, Purification and Identification of Bovine Lung Peptides and Its Antioxidant Effects on HAntioxidants (Basel, Switzerland) · 2025Article
- Anti-Inflammatory Drugs for Alcoholic Liver Disease: A Systematic Review on Survival and Adverse Events.International journal of hepatology · 2025Review
- Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1.JHEP reports : innovation in hepatology · 2024Article
- Pathological Role of Oxidative Stress in Aflatoxin-Induced Toxicity in Different Experimental Models and Protective Effect of Phytochemicals: A Review.Molecules (Basel, Switzerland) · 2023Review
- Silymarin Encapsulated Liposomal Formulation: An Effective Treatment Modality against Copper Toxicity Associated Liver Dysfunction and Neurobehavioral Abnormalities in Wistar Rats.Molecules (Basel, Switzerland) · 2023Article
- Carbenoxolon Is Capable to Regulate the Mitochondrial Permeability Transition Pore Opening in Chronic Alcohol Intoxication.International journal of molecular sciences · 2021Article
- Beneficial Effects of Betaine: A Comprehensive Review.Biology · 2021Review
- Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.Toxicology reports · 2021Review
- The Impact of Acute or Chronic Alcohol Intake on the NF-κB Signaling Pathway in Alcohol-Related Liver Disease.International journal of molecular sciences · 2020Review
- Liver-lung axes in alcohol-related liver disease.Clinical and molecular hepatology · 2020Review
- Article
- The Functions of Mitochondrial 2',3'-Cyclic Nucleotide-3'-Phosphodiesterase and Prospects for Its Future.International journal of molecular sciences · 2020Review
- Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support.International journal of molecular sciences · 2019Review
- Alcoholic Liver Disease: Current Mechanistic Aspects with Focus on Their Clinical Relevance.Biomedicines · 2019Review
- Ethanol withdrawal mitigates fatty liver by normalizing lipid catabolism.American journal of physiology. Gastrointestinal and liver physiology · 2019Article
- [Research advances in the treatment of hepatic fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Review
- Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression.Journal of hepatology · 2017Article
- Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.Hepatology (Baltimore, Md.) · 2017Article
- Alcoholic Liver Disease: Pathogenesis and Current Management.Alcohol research : current reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Alcoholic liver disease (ALD) remains a major cause of morbidity and mortality worldwide. For example, the Veterans Administration Cooperative Studies reported that patients with cirrhosis and superimposed alcoholic hepatitis had a 4-year mortality of >60% (worse than many common cancers such as breast and prostate). The cornerstone for therapy for ALD is lifestyle modification, including drinking cessation and treatment of decompensation, if appropriate. Nutrition intervention has been shown to play a positive role on both an in-patient and out-patient basis. Corticosteroids are effective in selected patients with alcoholic hepatitis, and treatment with pentoxifylline appears to be a promising anti-inflammatory therapy. Recent studies have indicated anti-TNFalpha therapy, at least for alcoholic hepatitis. Some complementary and alternative medicinal agents, such as milk thistle and S-adenosylmethionine, may be effective in alcoholic cirrhosis. Treatment of the complications of ALD can improve the quality of life and, in some cases, decrease short-term mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.